Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations.
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2014
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2013 Primary endpoint 'Progression-free-survival' has been met according to information reported in an ASCO-2013 abstract.
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 May 2012 Additional lead trial investigator (Yi-Long Wu) identified as reported by ClinicalTrials.gov.